The objective of this study was to assess the impact of ⁶⁸Ga-prostate-specific membrane antigen (⁶⁸Ga-PSMA) PET/CT on the management of prostate cancer in patients with biochemical recurrence (BCR). Methods: Documented management plans before and after ⁶⁸Ga-PSMA PET/CT in 100 patients with BCR were retrospectively reviewed, and changes in plans were recorded. Results: Management changed after ⁶⁸Ga-PSMA PET/CT in 39 patients (39%). The management changes occurred in 23 (33.8%) of 68 patients with radical prostatectomy and 16 (50%) of 32 patients previously treated with radical radiotherapy. Positive scan results (P < 0.001) and higher prostate-specific antigen (PSA) levels (P = 0.024) were associated with management changes. No significant association with management change was found for Gleason grade, stage, presence of metastatic disease, PSA velocity, or PSA doubling time. Conclusion: ⁶⁸Ga-PSMA PET/CT altered management in 39% of patients with BCR, and changes occurred more often in patients with radical radiotherapy treatment, positive ⁶⁸Ga-PSMA scan results, and higher PSA levels.

本研究的目的是评估⁶⁸ Ga-前列腺特异性膜抗原 ( ⁶⁸ Ga-PSMA) PET/CT 对生化复发 (BCR) 患者前列腺癌治疗的影响。方法：回顾性审查 100 例 BCR 患者⁶⁸ Ga-PSMA PET/CT 前后记录的管理计划，并记录计划的变化。结果： 39 名患者 (39%) 接受⁶⁸ Ga-PSMA PET/CT 治疗后，治疗发生了变化。 68 名接受根治性前列腺切除术的患者中有 23 名（33.8%）发生了管理变更，32 名既往接受根治性放疗的患者中有 16 名（50%）发生了管理变更。阳性扫描结果 ( P < 0.001) 和较高的前列腺特异性抗原 (PSA) 水平 ( P = 0.024) 与管理变化相关。未发现格里森分级、分期、转移性疾病的存在、PSA 速度或 PSA 倍增时间与管理变化存在显着关联。结论： ⁶⁸ Ga-PSMA PET/CT 改变了 39% 的 BCR 患者的治疗，并且这种变化在接受根治性放疗、 ⁶⁸ Ga-PSMA 扫描结果阳性和较高 PSA 水平的患者中更常见。